Opus Genetics, Inc. IRD
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-11.42
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $14.2M | -$49.6M | — | — | $15.3M |
| 2024 | $11.0M | -$57.5M | — | — | $6.7M |
| 2023 | $19.0M | -$10.0M | — | — | $49.9M |
| 2022 | $39.9M | $17.9M | — | — | $46.2M |
| 2021 | $589,000 | -$56.7M | — | — | $22.2M |
| 2020 | $0 | -$24.6M | — | -$6.8M | -$13.5M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -11.42 (distress)
- Working capital / assets 0.841
- Retained earnings / assets -3.754
- EBIT / assets -0.768
- Equity / liabilities 0.44
Source: SEC EDGAR filings · CIK 0001228627 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.